Phase 2 N=4 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease
Charcot Marie Tooth Disease
Primary: Number of Participants With a Decrease in Cramp Duration — 2; 0 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=80 Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
Charcot-Marie-Tooth Disease · Hereditary Neuropathy With Liability to Pressure Palsies · Genetic Disorders
Primary: Safety and Tolerability of PXT3003 — 21; 21; 19; 19 Participants
Phase 3 N=323 Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT)
Charcot-Marie-Tooth Disease Type 1A
Primary: Overall Neuropathy Limitation Scale (ONLS) Total Score — 3.33; 3.05; 3.23; 3.25 Scores on the ONLS — p=0.008
Phase 2 N=12 The Safety and Tolerability of Engensis (VM202) in Patients With Charcot-Marie-Tooth Disease Subtype 1A (CMT1A)
CMT
Primary: Safety of Intramuscular (IM) Injections of Engensis in Participants — 1; 1; 1; 1 Participants
N/A N=41 Neurogenic Inflammation in Diabetes
Diabetes Mellitus · Polyneuropathies · Arthropathy, Neurogenic
Primary: Induration Size as a Response to Intracutaneous Candida Albicans. — 4; 6; 5; 4 millimeters — p=0.84
N/A N=44 Reversing Diabetic Peripheral Neuropathy Through Exercise
Peripheral Neuropathy · Diabetes
Primary: Body Mass Index (BMI) — 30.7 kg/m^2
Phase 2 N=132 Topiramate for Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome (CSPN)
Cryptogenic Sensory Peripheral Neuropathy in Metabolic Syndrome
Primary: Intraepidermal Nerve Fiber Density (IENFD) — -0.6064; -0.396 fibers/mm/year (52 weeks)
Phase 3 N=7 Investigating the Use of Prolia (Denosumab) in the Treatment of Acute Charcot Neuroarthropathy
Charcot Joint of Foot
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] — 0; 7 Participants
N/A N=102 Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan
Small Fiber Neuropathy · Fabry Disease · Ehlers Danlos Syndrome
Primary: Number of Patients With Abnormal Electrochemical Skin Conductance in the Different Study Groups Who Have Clinical Symptoms Consistent With Small Fiber Polyneuropathy…
Phase 2 N=14 MC-5A for Chemotherapy Induced Peripheral Neuropathy
Neuropathy, Paraneoplastic
Primary: Change in Mechanical Visual Analog Scale (mVAS) Using Quantitative Sensory Pain Testing (QSPT) — 5.14; -2.00; 1.25; 6.76 Millimeters
Phase 2 N=15 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study
Chronic Inflammatory Demyelinating Polyneuropathy · Peripheral Neuropathy · Charcot-Marie-Tooth Disease
Primary: Motor Nerve Conduction Velocity (m/Sec) — 1.67 m/s — p=0.7615
Phase 2 N=59 Effectiveness of Mexiletine for Treating People With Non-Dystrophic Myotonia
Myotonia · Non-Dystrophic Myotonia
Primary: Patient-reported Stiffness on the IVR — 2.53; 4.21; 1.60; 5.27 units on a scale — p=<0.001
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
Phase 2 N=20 Efficacy of Teriparatide in Diabetic Inactive Charcot Neuroarthropathy of Foot
Diabetic Neuropathic Arthropathy
Primary: SUV Max on PET/CT Scan at 12 Months — 26.1; 22.9 g/ml
N/A N=15 Repetitive Transcranial Magnetic Stimulation as Therapy in Hereditary Spastic Paraplegia and Adrenomyeloneuropathy
Hereditary Spastic Paraplegia · Adrenomyeloneuropathy
Primary: Change From Baseline Walking Time in 10 Meter Walk Test to the Measurement Taken Directly After rTMS — -5.41; 1.70 seconds
N/A N=92 DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls
Duchenne Muscular Dystrophy
Primary: Number of Subjects With an Adverse Event. — 1; 0; 0; 0 participants
N/A N=442 Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Cerebrotendinous Xanthomatosis (CTX)
Primary: Number of Participants Who Had Positive Genetic Test Results — 4 Participants
Phase 2 N=12 An Open Label Phase 2 Study of ManNAc in Subjects With GNE Myopathy
GNE Myopathy
Primary: Mean Area Under the Curve (AUClast) of Plasma ManNAc (Baseline-adjusted) — 7461; 9432 hr*ng/mL
N/A N=60 Metatarsal Phalangeal Joint Deformity Progression - R01
Diabetes Mellitus (DM)
Primary: Change in Metatarsal Phalangeal Joint Angle (Degrees) in People With Diabetes From Baseline and at a 3-year Period — 0.8; -0.1 degrees
N/A N=31 Thumb Osteoarthritis: A Cross-Sectional Study of Mechanisms
Carpometacarpal Osteoarthritis
Primary: Australian Canadian OA Hand Index (AUSCAN) — 3.3; 1.3; 2.0; 1.6 score on a scale
N/A N=14 Electrical Stimulation in Diabetic Peripheral Neuropathy
NMES · Control
Primary: Nerve Conduction Speed (Common Peroneal Nerve) — 33.93; 44.1; 41.63; 44.13 m/sec
N/A N=140 Effect of Exercise and Surgical Weight Loss on Polyneuropathy
Polyneuropathies · Obesity · Bariatric Surgery Candidate
Primary: Intraepidermal Nerve Fiber Density (IENFD) at the Proximal Thigh — 11.9; 12.7; 9.8; 11 fibers/mm — p=0.15
Phase 4 N=12 Growth and Development Study of Alglucosidase Alfa
Pompe Disease · Glycogen Storage Disease Type II (GSD-II) · Acid Maltase Deficiency Disease
Primary: Recumbent Height/Length of Participants in Centimeters (cm) — 80.4; 93.8; 67.7; 91.1 cm
N/A N=21 Neuromuscular Electrical Stimulation (NMES) in Patients With Intermittent Claudication
Intermittent Claudication · Peripheral Vascular Disease
Primary: Change From Baseline in Initial Walking Distance — 64.3 metres
Phase 2 N=18 L-Serine Supplementation in Hereditary Sensory Neuropathy Type 1
Hereditary Sensory and Autonomic Neuropathy Type I
Primary: Charcot Marie Tooth Neuropathy Score — 25.67; 20.22 scores on a scale
N/A N=78 Effects of Foot Muscle Strengthening in Daily Activity in Diabetic Neuropathic Patients
Diabetic Neuropathies
Primary: Daily Physical Activity — 8744; 7373 number of steps per week
Phase 4 N=402 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations
Cryptogenic Sensory Polyneuropathy
Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…